Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $3.10 USD
Change Today -0.26 / -7.74%
Volume 2.3M
BIOC On Other Exchanges
Symbol
Exchange
NASDAQ CM
Stuttgart
As of 8:10 PM 03/6/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

5810 Nancy Ridge Drive

Suite 150

San Diego, CA 92121

United States

Phone: 858-320-8200

Fax: 858-320-8225

aracterize their patients’ tumors on a real-time basis by analyzing CTCs and ctDNA found in standard blood draws. The company’s approach is to develop and commercialize CTC and ctDNA tests and services to enable the company to offer to oncologists standard blood sample based, real-time, testing solutions for a range of solid tumor types, starting with breast cancer and progressing to future launches of tests for non-small cell lung cancer, gastric cancer, colorectal cancer, prostate cancer, melanoma and others, to improve patient treatment with better prognostic and predictive tools. Research and Development The company incurred research and development expenses of $3.1 million, as of December 31, 2013. Patents and Technology The company’s patent portfolio consists of three issued U.S. patents, six pending U.S. patent applications and corresponding foreign patents and foreign patent applications. These patents and patent applications are related to various aspects of its and planned CTC and ctDNA tests, including its CEE microfluidic channels, its CEE-Sure blood collection tubes, CEE-Cap antibody capture cocktail, CEE-Enhanced staining methodology, and CEE-Selector technology for mutation detection. Sales and Marketing The company’s sales and marketing activities consist of working with its partners and establishing its own direct sales force in the United States focused on selling directly to community oncologists in hospitals, cancer centers and offices, as well as biopharma companies and supporting its partners as technical specialists and medical science liaisons. Significant Events In October 2014, Biocept, Inc. announced the furthering of its collaboration with The University of Texas MD Anderson Cancer Center regarding studies focused on patients diagnosed with ovarian cancer. In October 2014, Biocept, Inc. and Rosetta Genomics, Ltd. announced a collaboration that would combine both companies' platform technologies in an innovative approach to cancer diagnostics. In January 2015, Biocept, Inc. and Insight Genetics announced their collaboration to generate an enhanced diagnostic for the expression and mutation of ALK, a major therapeutic target in the treatment of non-small cell lung cancer. Competition In addition to Janssen Diagnostics, LLC and Atossa Genetics, the company’s competitors include public companies such as Alere (Adnagen) and Illumina, as well as companies, including Apocell, EPIC Sciences, Clearbridge Biomedics, Cynvenio Biosystems, Fluxion Biosciences, RareCells, ScreenCell and Silicon Biosystems. History Biocept, Inc. was founded in 1997 in California.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BIOC:US $3.10 USD -0.26

BIOC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Atossa Genetics Inc $1.97 USD -0.04
BioMerieux €96.72 EUR -0.08
Daiichi Sankyo Co Ltd ¥1,986 JPY +37.50
Fluidigm Corp $42.25 USD -1.28
Illumina Inc $193.14 USD -6.99
View Industry Companies
 

Industry Analysis

BIOC

Industry Average

Valuation BIOC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 195.2x
Price/Book 4.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 367.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOCEPT INC, please visit www.biocept.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.